GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News: BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the initiation of a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB®, its novel allogeneic bone cell therapy product. The Competent Authorities […]